Abstract
Clinical studies have highlighted the efficacy of anti-PD-1 (αPD-1) treatment in patients with hypermutated tumors deficient in DNA mismatch repair (MMRD). However, the responsiveness of MMRD tumors to αPD-1 treatment is variable, and the cause to explain this variability remains unclear.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
